Lionel K. Tan
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.
Journal: The Pediatric infectious disease journal
Published: February 04, 2026
Model-informed Dolutegravir Dose Selection in Pediatrics With First-generation INSTI Resistance.
Journal: The Pediatric infectious disease journal
Published: February 04, 2026
Safety and pharmacokinetics of GSK3494245, a highly selective Leishmaniasis kinetoplastid proteasome inhibitor for the treatment of visceral leishmaniasis: A Phase 1, randomized, single ascending dose escalation study in healthy participants.
Journal: PLoS neglected tropical diseases
Published: July 11, 2025
Target product profile and discovery and development path for novel cryptococcal disease treatments.
Target product profile and discovery and development path for novel cryptococcal disease treatments.
Journal: The Journal of infection
Published: May 30, 2025
Developing and streamlining clinical trial services to support pediatric drug development across 21 countries in Europe: insights from the conect4children (c4c) network.
Journal: Frontiers in medicine
Published: November 20, 2024
"Common sense is hard work" but benefits from persistent collaboration: Lessons learnt from the development of The Collaborative Network for European Clinical Trials for Children (c4c) to support the conduct of paediatric clinical trials of medicines.
Journal: Contemporary clinical trials communications
Published: August 14, 2024
Efficacy and Safety of the Two-Drug Regimen Dolutegravir-Lamivudine in Adolescents Living With HIV-1 Naive to Antiretroviral Therapy at 48 Weeks (DANCE): A Single-Arm, Open-Label, Phase 3b Trial.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: July 26, 2024
A Model-Based Approach Supporting Abacavir/Dolutegravir/Lamivudine Fixed-Dose Combination Approval in Children Living with HIV-1.
Journal: Journal of clinical pharmacology
Published: June 27, 2024
Risk factors for bloodstream infections due to carbapenem-resistant Enterobacterales: a nested case-control-control study.
Journal: The Journal of antimicrobial chemotherapy
Published: December 18, 2023
Advancing research and development of anti-infectives for children with a focus on antiretroviral therapy: A clinical development perspective.
Journal: International journal of antimicrobial agents
Published: December 01, 2023
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Journal: Malaria journal
Published: August 31, 2023
Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA).
Journal: Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
Published: July 16, 2023
Last Updated: 09/26/2026